Musher D M, Groover J E, Watson D A, Pandey J P, Rodriguez-Barradas M C, Baughn R E, Pollack M S, Graviss E A, de Andrade M, Amos C I
Medical Service (Infectious Disease Section), Houston Veterans Affairs Medical Center, TX 77030, USA.
J Investig Med. 1997 Feb;45(2):57-68.
Genetic regulation of immunoglobulin G(IgG) responses to pneumococcal capsular polysaccharides (PPS), has been demonstrated in mice but not in humans. Earlier studies from this laboratory showed that healthy adults have a varying capacity to generate IgG antibody to PPS; this study sought to determine whether this capacity is genetically controlled.
A 23-valent pneumococcal vaccine was administered to 72 unrelated White adults, 4 nuclear families, and 61 members of an extended Ashkenazic Jewish family. Selected individuals later received one or more doses of the vaccine and/or a single dose of protein-conjugated PPS. Four to six weeks after each vaccination, IgG to PPS was measured by ELISA. Immunoglobulin allotypes and HLA types were determined by standard techniques.
After vaccination, 53% of the 72 unrelated White adults had measurable levels of IgG antibody to all of 10 PPS studied (high-level responders), 36% had IgG to 6-9 PPS, and 11% had IgG to < or = 5 of 10 PPS (low-level responders). Persons who did not make IgG to an individual PPS also failed to make IgM or IgA to that antigen. Low-level responders had reduced mean IgG levels to PPS to which they did make IgG; nevertheless, their total serum concentrations of IgG, IgG2, IgA, and IgM were normal, and each made IgG2 to at least one PPS, all indicating that a global defect in Ig production was not responsible. The responder status of offspring was highly associated with that of their parents. Segregation analysis of 61 Ashkenazic family members revealed that the capacity to generate anti-PPS IgG was inherited in a mixed, codominant fashion. Repeated vaccination or administration of protein-conjugated PPS did not elicit measurable IgG in nonresponders. The HLA type was not associated with antibody responses. An association between IgG level and Gm(23)+ allotype was observed in unrelated Whites but not in Ashkenazic Jews.
Thus, humans exhibit a variable capacity to respond to PPS. This response is hereditable in a mixed, codominant fashion. The absence of IgG to a PPS, even after antigen is presented in a protein-conjugate form, may reflect a genetically mediated failure to recognize polysaccharide antigens. Since persons who respond to fewer PPS also have lower levels of IgG to PPS to which they do respond, genetically determined deficiencies in events that involve proliferation of committed B lymphocytes may also play a role.
免疫球蛋白G(IgG)对肺炎球菌荚膜多糖(PPS)反应的遗传调控在小鼠中已得到证实,但在人类中尚未得到证实。本实验室早期的研究表明,健康成年人产生针对PPS的IgG抗体的能力各不相同;本研究旨在确定这种能力是否受基因控制。
给72名无亲缘关系的白人成年人、4个核心家庭以及一个阿什肯纳兹犹太大家庭的61名成员接种了23价肺炎球菌疫苗。部分个体随后接受了一剂或多剂该疫苗和/或一剂蛋白结合PPS。每次接种疫苗后4至6周,通过酶联免疫吸附测定法(ELISA)检测针对PPS的IgG。通过标准技术确定免疫球蛋白异型和人类白细胞抗原(HLA)类型。
接种疫苗后,72名无亲缘关系的白人成年人中,53%对所研究的全部10种PPS均有可检测水平的IgG抗体(高反应者),36%对6 - 9种PPS有IgG,11%对10种PPS中的≤5种有IgG(低反应者)。对某一种PPS不产生IgG的人,对该抗原也不产生IgM或IgA。低反应者对其确实产生IgG的PPS的平均IgG水平较低;然而,他们血清中IgG、IgG2、IgA和IgM的总浓度正常,且每个人至少对一种PPS产生IgG2,所有这些都表明并非存在Ig产生的整体缺陷所致。后代的反应状态与其父母的反应状态高度相关。对61名阿什肯纳兹家庭成员的分离分析显示,产生抗PPS IgG的能力是以混合共显性方式遗传的。对无反应者重复接种疫苗或给予蛋白结合PPS均未引发可检测到的IgG。HLA类型与抗体反应无关。在无亲缘关系的白人中观察到IgG水平与Gm(23)+异型之间存在关联,但在阿什肯纳兹犹太人中未观察到这种关联。
因此,人类对PPS的反应能力存在差异。这种反应是以混合共显性方式遗传的。即使以蛋白结合形式呈现抗原后仍对一种PPS不产生IgG,可能反映了在识别多糖抗原方面存在基因介导的缺陷。由于对较少PPS有反应的人对其有反应的PPS的IgG水平也较低,在涉及已分化B淋巴细胞增殖的事件中,基因决定的缺陷可能也起了作用。